Condition: Idiopathic Pulmonary Arterial Hypertension · Heritable Pulmonary Arterial Hypertension · Scleroderma Associated Pulmonary Arterial Hypertension · Sponsor: Vanderbilt University Medical Center
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
This description comes directly from the study's public registry record.
Kelly L Fox · 800-288-0378 · Kelly.Burke@vumc.org
Shannon Cordell, BSN · 615-343-8277 · shannon.eason@vumc.org
Always discuss trial participation with your own doctor first.
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01884051